Immunitrack ApS Competitors

CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates. It also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at www.curevac.com.

Adaptimmune is a fully integrated cell therapy company, designed and built from the ground up with four U.K.- and U.S.-based biotechnology hub locations. Our comprehensive capabilities and teams include preclinical research, clinical development, translational sciences, autologous and allogeneic manufacturing, and in-house commercial and corporate operations. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page. Adaptimmune only accepts employment applications through our corporate website at Adaptimmune.com/Careers and through the ‘Easy Apply’ feature on LinkedIn. If you receive an unsolicited message from someone purporting to represent Adaptimmune, please be cautious and do not provide any personal or financial information, except through the approved application process. If you have any questions regarding an unsolicited message or offer, please contact Talent.AcquisitionUSA@adaptimmune.com to confirm whether the communication is legitimate.

ImmunoGen is now part of AbbVie. AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. For more information about AbbVie, please visit us at www.abbvie.com. Follow AbbVie on LinkedIn for future updates. Review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.